U.S. Patent Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10563645		
Filing Date		2006-01-06		
First Named Inventor Johan		nnis F R. BLACQUIERE ET AL		
Art Unit		3627		
Examiner Name				
Attorney Docket Number		NI 030867		

		·			U.S.	PATENTS	-		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear		
	1	6385690	B1	2002-05	5-07	IIDA ET AL				
If you wisl	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.	-	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines wher ant Passages or Rele s Appear	
	1	20010038704	A1	2001-11	1-08	ITO ET AL				
	2	20020078295	A1	2002-06	i-20	SHAATH ET A	L			
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	TE
	1	0730274	EP		A2	1996-09-04	INCAT SOFTWAR	E INC		
	2	0730274	EP		B1	1996-09-04	INCAT SOFTWAR	E INC		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

EΡ

publisher, city and/or country where published.

A2 2002-03-27

3 1191536

	Application Number		10563645
	Filing Date		2006-01-06
First Named Inventor Johan		Johan	nnis F R. BLACQUIERE ET AL
	Art Unit		3627
Examiner Name Attorney Docket Number			
		er	NL030867

KK TOSHIBA

	4	1195767	EP	A1	2002-04-10	THOMPSON-BRANDT		
	5	1039464	EP	A2	2000-09-27	SAMSUNG CO LTD		
	6	0124179	wo	A1	2001-04-05	MATSUSHITA IND CO		
	7	03012780	wo	A2	2003-02-13	ENTERPRISE CORP		
	8	02086729	wo	A2	2002-10-31	KPENV		
	9	0122416	wo	A1	2001-03-29	KPENV		
	10	0942426	EP	A2	1999-09-15	NIPPON CO. LTD		
	11	0942426	EP	B1	1999-09-15	NIPPON CO LTD		
If you wish	If you wish to add additional Foreign Patent Document citation information please click the Add button Add							
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner	Cite					the article (when appropriate, pages(s), volume-is		T5

No

1	
i	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at year-USPTO,QQV or MPEP 901.94. ² Either office that issued the document, by the hor-left code (WIPO Standard ST.3.) ² Evolution protection for the part of the Emperor must protected the sears inumber of the Patend Teach and protection for the sear of the Emperor must protected the sears inumber of the Patend Teach (Fig. 1) and (Fig.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10563645		
	Filing Date		2006-01-06		
First Named Inventor Johan		Johan	nis F R. BLACQUIERE ET AL		
	Art Unit		3627		
Examiner Name Attorney Docket Number					
		ec	NI 030867		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 137(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ Nor

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael E. Belk/	Date (YYYY-MM-DD)	2007-03-19				
Name/Print	Michael E. Belk	Registration Number	33,357				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.